Anti-Human IL6R Recombinant Antibody (Tocilizumab/Atlizumab) (CAT#: TAB-026)

Figure 1 The inhibitory profile of tocilizumab is independent of IL-6R expression.

A , equal numbers of Ba/F3-gp130 cells were cultured for 2 days with 10 ng/ml Hyper-IL-6, 10 ng/ml human, or 10 ng/ml murine IL-6. As a control, Ba/F3-gp130 cells were cultured without any cytokine. B , equal numbers of Ba/F3-gp130, Ba/F3-gp130-hIL-6R, or Ba/F3-gp130-mIL-6R cells were cultured for 2 days with 10 ng/ml human IL-6 and increasing concentrations of the anti-human-IL-6R antibody tocilizumab (0.001–10,000 ␮ g/ml). C , equal numbers of Ba/F3-gp130 or Ba/F3-gp130-hIL-6R cells were cultured for 2 days with 10 ng/ml hIL-6 plus increasing concentrations of shIL-6R as indicated. D , equal numbers of Ba/F3-gp130, Ba/F3-gp130-hIL-6R, or Ba/F3-gp130-mIL-6R cells were cultured for 2 days with 10 ng/ml human IL-6 plus 200 ng/ml shIL-6R and increasing concentrations of the anti-human-IL-6R antibody tocilizumab (0.001– 10,000 ug/ml). Statistical analysis was carried out using a paired Student's t test, and statistical significance was p< 0.01 (**). The proliferation measured with the lowest inhibitor concentration was about the same as without inhibitor.

Garbers, C. , Thaiss, W. , Jones, G. W. , Waetzig, G. H. , Lorenzen, I. , & Guilhot, F. , et al. (2011). Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor *. Journal of Biological Chemistry, 286.

Figure 1 Anti-Human IL6R Antibody (Tocilizumab/Atlizumab) (TAB-026) in ELISA

ELISA analysis of TAB-026 was performed by coating with Recombinant Human IL6R Protein.

Figure 2 Anti-Human IL6R Antibody (Tocilizumab/Atlizumab) (TAB-026) in WB

Western blot analysis of TAB-026 was performed with Recombinant Human IL6R Protein.
Lane 1: Non-Reducing Antigen (1 μg)
Lane 2: Reducing Antigen (1 μg)